Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,689 result(s) found for: placebo. Displaying page 237 of 635.
    «« First « Previous 233  234  235  236  237  238  239  240  241  Next» Last»»
    EudraCT Number: 2015-002581-23 Sponsor Protocol Number: JBT101-CF-001 Start Date*: 2015-12-03
    Sponsor Name:Corbus Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis
    Medical condition: Cystic Fibrosis Cystic Fibrosis is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections, fibrosis of the lungs and digestive tract and abno...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004337-32 Sponsor Protocol Number: 3101-303-002 Start Date*: 2020-02-12
    Sponsor Name:Allergan Limited
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PR...
    Medical condition: Chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066636 Chronic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) SE (Completed) PL (Completed) DE (Completed) DK (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002324-32 Sponsor Protocol Number: CLJN452D12201C Start Date*: 2019-12-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001364-38 Sponsor Protocol Number: WN29922 Start Date*: 2018-06-18
    Sponsor Name:Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche LTD
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE
    Medical condition: Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) LT (Completed) DE (Completed) HU (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000762-11 Sponsor Protocol Number: 62113-55115 Start Date*: 2014-10-20
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxoru...
    Medical condition: High Grade Undifferentiated Uterine Sarcoma (HGUS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046821 Uterine sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002148-56 Sponsor Protocol Number: ACT-CS-005 Start Date*: 2021-07-22
    Sponsor Name:ACTICOR BIOTECH
    Full Title: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, MULTINATIONAL, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE DOSE, ADAPTIVE EFFICACY AND SAFETY STUDY OF GLENZOCIMAB USED AS AN ADD-ON THERAPY ON TOP OF STANDA...
    Medical condition: Acute ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) DK (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004956-12 Sponsor Protocol Number: CORT125134-456 Start Date*: 2021-02-24
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-...
    Medical condition: Hypercortisolism
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004860 10020611 Hypercortisolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) BG (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001674-34 Sponsor Protocol Number: AG348-C-020 Start Date*: 2022-02-17
    Sponsor Name:AGIOS PHARMACEUTICALS, INC.
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005387-22 Sponsor Protocol Number: ACP-103-069 Start Date*: 2022-06-27
    Sponsor Name:Acadia Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
    Medical condition: Treatment of irritability associated with autistic disorder in children and adolescents with ASD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001458-24 Sponsor Protocol Number: ALN-TTR02-011 Start Date*: 2019-09-19
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (...
    Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) BG (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004350-26 Sponsor Protocol Number: I1F-MC-RHBA Start Date*: 2012-08-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) NL (Completed) AT (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005535-68 Sponsor Protocol Number: CLCQ908B2302 Start Date*: 2012-05-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10051598 Chylomicrons PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020718-26 Sponsor Protocol Number: WN25305 Start Date*: 2011-01-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled sympt...
    Medical condition: Adjunctive treatment of patients with sub-optimally controlled symptoms of schizophrenia. Sub-optimally controlled patients are defined as those who on their current medication have persistent symp...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000282-35 Sponsor Protocol Number: BO17705 Start Date*: 2004-09-29
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr...
    Medical condition: Metastatic clear cell renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7 10038415 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000091-32 Sponsor Protocol Number: 20050225 Start Date*: 2006-10-25
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized Phase 2 Trial of Double- Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open- Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women wit...
    Medical condition: HER2 Negative Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended) ES (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-016604-23 Sponsor Protocol Number: CACZ885I2207 Start Date*: 2010-05-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie...
    Medical condition: Impaired Glucose Tolerance and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023775-25 Sponsor Protocol Number: 3652-CL-0019 Start Date*: 2011-08-02
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacoki...
    Medical condition: Chronic abacterial Prostatitis/Chronic Pelvic Pain Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10064189 Chronic pelvic pain syndrome LLT
    14.1 100000004872 10009109 Chronic prostatitis LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) CZ (Completed) LT (Completed) LV (Completed) PL (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000261-21 Sponsor Protocol Number: 1399-0003 Start Date*: 2019-10-08
    Sponsor Name:Boehringer Ingelheim
    Full Title: A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy t...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000305-21 Sponsor Protocol Number: S306.2.008 Start Date*: 2006-09-06
    Sponsor Name:Solvay Pharmaceuticals
    Full Title: A randomized, placebo-controlled, double-blind, six-arm, dose escalation, multi-center study to evaluate the efficacy and safety of SLV306: 150, 300, 600 mg once daily, 150-300 mg twice daily and a...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) DK (Completed) HU (Completed) EE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-003684-41 Sponsor Protocol Number: 6213-006-03 Start Date*: 2007-11-01
    Sponsor Name:MSD Finland Oy
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Assess the Efficacy and Tolerability of MK-6213 Co-Administered With Atorvastatin in Patients with Primary Hypercho...
    Medical condition: Primary hypercholesterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 233  234  235  236  237  238  239  240  241  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 14:27:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA